Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to
vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95 …

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression …

Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a
common condition that presents with recurrent infection. SID is due to both the inherent …

Patients with cancer are at higher risk of more severe COVID-19 infection and have more
associated complications. The position paper describes the management of cancer patients …

In Deutschland leben aktuell circa 4 Mio. Menschen, die in ihrem Leben eine
Krebserkrankung diagnostiziert bekommen haben [171]. Im Zeitraum von 1980–2017 …

Simple Summary The urgency of the COVID-19 pandemic has led to accelerated vaccine
development within less than a year. Emerging data suggest that the ability of patients with …

Immunocompromised patients with hematologic malignancies are more susceptible to
COVID-19 and at higher risk of severe complications and worse outcomes compared with …

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy
against COVID-19, but its efficacy in patients with hematological malignancies is largely …

Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with chronic
lymphocytic leukemia (CLL). Indefinite therapy with BTKis, although effective, presents …